1278 related articles for article (PubMed ID: 33524282)
1. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.
Zhang R; Mylonakis E
Ann Intern Med; 2021 Feb; 174(2):JC17. PubMed ID: 33524282
[TBL] [Abstract][Full Text] [Related]
2. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium
Lancet; 2022 May; 399(10339):1941-1953. PubMed ID: 35512728
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Ader F;
BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
7. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
Paladugu S; Donato AA
Ann Intern Med; 2020 Jul; 173(2):JC4. PubMed ID: 32687756
[TBL] [Abstract][Full Text] [Related]
9. Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
Seyfi S; Latifi K; Amri Male P; Sadeghi Haddad Zavareh M; Ezoji K; Mohammadnia-Afrozi M
Int Immunopharmacol; 2021 Dec; 101(Pt B):108241. PubMed ID: 34688151
[TBL] [Abstract][Full Text] [Related]
10. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients.
Demir Önder K; Seremet Keskin A; Berk H; Seyman D; Öztoprak N
Turk J Med Sci; 2021 Dec; 51(6):2835-2849. PubMed ID: 34418000
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir (Veklury) for COVID-19.
Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
[No Abstract] [Full Text] [Related]
13. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system.
Coppock D; Baram M; Chang AM; Henwood P; Kubey A; Summer R; Zurlo J; Li M; Hess B
PLoS One; 2021; 16(6):e0252591. PubMed ID: 34115801
[TBL] [Abstract][Full Text] [Related]
15. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
16. Drug treatments for covid-19: living systematic review and network meta-analysis.
Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
18. Race to find COVID-19 treatments accelerates.
Kupferschmidt K; Cohen J
Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
[No Abstract] [Full Text] [Related]
19. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.
Flisiak R; Zarębska-Michaluk D; Berkan-Kawińska A; Tudrujek-Zdunek M; Rogalska M; Piekarska A; Kozielewicz D; Kłos K; Rorat M; Bolewska B; Szymanek-Pasternak A; Mazur W; Lorenc B; Podlasin R; Sikorska K; Oczko-Grzesik B; Iwaszkiewicz C; Szetela B; Pabjan P; Pawłowska M; Tomasiewicz K; Polańska J; Jaroszewicz J
Pol Arch Intern Med; 2021 Jan; 131(1):103-110. PubMed ID: 33382547
[No Abstract] [Full Text] [Related]
20. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
